Previous 10 | Next 10 |
ANI Pharmaceuticals (NASDAQ: ANIP ): Q2 Non-GAAP EPS of $1.44 beats by $0.16 ; GAAP EPS of $0.53 beats by $0.01 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BAUDETTE, Minn. , Aug. 7, 2019 /PRNewswire/ -- For the second quarter 2019: Net revenues of $54.4 million , an increase of 15% versus prior year GAAP net income of $6.6 million and diluted GAAP earnings per share of $0.53 , increases of 137% and 130% versus prior year, res...
AMAG , ANIP , ATHM , ATKR , AVA , BCOR , BV , CNP , CORE , CPRI , CSTE , CVS , CYBR , DNR , DOC , ETM , EVOP , FUN , GOLF , GTN , HL , HZNP , ICPT , INGN , INXN , IONS , JELD , KELYA , LAMR , LL , LXP , MFA , MIDD , NRG , NVMI , NXST , NYT , ODP , OMI ...
BAUDETTE, Minn. , July 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2019 financial results on Wednesday, August 7, 2019 , before the opening of the U.S. financial markets. The earni...
Company Thesis ANI Pharmaceuticals' ( ANIP ) cortrophin will likely be the sole generic competitor to Mallinckrodt's ( MNK ) blockbuster H.P. Acthar Gel, besting Assertio Therapeutic s' ( ASRT ) investigative cosyntrophin by a wide margin. The company's 5 key branded launches in the past fis...
ANI Pharmaceuticals (NASDAQ: ANIP ) has launched Ranitidine Capsules, 150mg and 300mg. More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
BAUDETTE, Minn. , June 25, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Ranitidine Capsules, 150mg and 300mg. The current annual U.S. market for this product is approximately $40 million , according to Iqvia/IMS Health. Art...
BAUDETTE, Minn. , June 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received FDA approval of its Prior Approval Supplement for Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml, indicated for the treatment of various infec...
ANI Pharmaceuticals ( ANIP +2.3% ) has acquired a pipeline of seven development stage generic products from Coeptis Pharmaceuticals, Inc. for $2.3M in cash and up to $12M in additional development and commercial milestones. More news on: ANI Pharmaceuticals, Inc., Merger & acquisit...
BAUDETTE, Minn. , June 18, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired a pipeline of seven development stage generic products from Coeptis Pharmaceuticals, Inc. for $2.3 million dollars in cash and up to $12.0 mil...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, prior to the market open. Nikh...
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...